1. Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, et al.. Polycystic ovary syndrome: A Comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci . 2022; 23(2): 583. [DOI:10.3390/ijms23020583] [PMID] []

2. Liu x, Herbison A. Dopamine regulation of gonadotropin-releasing hormone neuron excitability in male and female mice. Endocrinology 2013; 154(1): 340-50. [DOI:10.1210/en.2012-1602] [PMID]

3. Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007; 30(5):194-202. [DOI:10.1016/j.tins.2007.03.006] [PMID]

4. Jaber M, Robinson SW, Missale C, Caron MG. Dopamine receptors and brain function. Neuropharmacology. 1996; 35(11):1503-19. [DOI:10.1016/S0028-3908(96)00100-1] [PMID]

5. Romero-Picó A, Novelle MG, Folgueira C, López M, Nogueiras R, Diéguez C. Central manipulation of dopamine receptors attenuates the orexigenic action of ghrelin. Psychopharmacology. 2013; 229(2): 275-83 [DOI:10.1007/s00213-013-3096-7] [PMID]

6. Goshima Y, Masukawa D, Kasahara Y, Hashimoto T. L-DOPA and its receptor GPR143: implications for pathogenesis and therapy in parkinson's disease. Front Pharmacol. 2019; 10:1119. [DOI:10.3389/fphar.2019.01119] [PMID] []

7. Schalla MA, Stengel A. The role of the gastric hormones ghrelin and nesfatin-1 in reproduction. Int J Mol Sci. 2021; 22(20): 11059. [DOI:10.3390/ijms222011059] [PMID] []

8. Caminos JE, Tena-Sempere M, Gaytán F, Sanchez-Criado JE., Barreiro ML, Nogueiras R, et al. Expression of ghrelin in the cyclic and pregnant rat ovary. Endocrinology. 2003; 144: 1594-1602. [DOI:10.1210/en.2002-221058] [PMID]

9. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschöp M, Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: Correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab. 2002; 87:5625-29. [DOI:10.1210/jc.2002-020776] [PMID]

10. Sadeghzadeh A, Bayrami A, Mahmoudi F, Khazali H, Asadi A. The effects of interaction of dopaminergic and kisspeptin neural pathways on ghrelin secretion in rats. J Paramed Sci. 2018; 9(1):29-35.

11. Gómez R, Ferrero H, Delgado-Rosas F, Gaytan M, Morales C, Zimmermann RC, Simón C, et al. Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. J Clin Endocrinol Metab. 2011; 96(8): 2484-92. [DOI:10.1210/jc.2011-0075] [PMID]

12. Haghighat Gollo K, Mahmoudi F, Bayrami A, Zahri S. Influences of L-DOPA and blocking dopamine receptors on aromatase gene expression and serum concentration of LH in polycystic ovary syndrome model rats. JABS. 2020; 10(3):2448-55.

13. Lhosrobakhsh F, Moloudi MR, Shoja K, Mohammadi S. Effect of alpha- lipoic acid on pancreatic optic atrophy 1(OPA1) gene expression in male rat model of obstructive cholestasis and cirrhosis. SJKU. 2019; 24(5):120-34. [DOI:10.29252/sjku.24.5.120]

14. Khazali H, Mahmoudi F, Janahmadi M. Hypothalamic KiSS1/GPR54 gene expressions and luteinizing hormone plasma secretion in morphine treated male rats. Int J Fertil Steril. 2018; 12(3):223-8.

15. Gambineri A, Pagotto U, Tschöp M, Vicennati V, Manicardi E, Carcello A, et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest. 2003; 26(7): 629-34. [DOI:10.1007/BF03347020] [PMID]

16. Akalu Y, Derbew Molla M, Dessie G, Ayelign B. Effect of ghrelin on body systems. Int J Endocrinol. 2020; 2020: 1385138. [DOI:10.1155/2020/1385138] [PMID] []

17. Tang R, Ding X, Zhu J. Kisspeptin and polycystic ovary syndrome. Front Endocrinol (Lausanne). 2019; 10: 298. [DOI:10.3389/fendo.2019.00298] [PMID] []

18. Iwakura H, Ariyasu H, Hosoda H, Yamada G, Hosoda K, Nakao K, et al. Oxytocin and dopamine stimulate ghrelin secretion by the ghrelin-producing cell line, MGN3-1 in vitro. Endocrinology. 2011; 152(7): 2619-25. [DOI:10.1210/en.2010-1455] [PMID]

19. Weinberg ZY, Nicholson ML, Currie. PJ. 6-Hydroxydopamine lesions of the ventral tegmental area suppress ghrelin's ability to elicit food-reinforced behavior. Neurosci Lett. 2011; 499(2): 70-3. [DOI:10.1016/j.neulet.2011.05.034] [PMID]

20. Jiang H, Betancourt L, Smith RG. Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol. 2006; 20(8):1772-85. [DOI:10.1210/me.2005-0084] [PMID]

21. Romero-Picó A, Novelle MG, Folgueira C, López M, Nogueiras R, Diéguez C. Central manipulation of dopamine receptors attenuates the orexigenic action of ghrelin. Psychopharmacology (Berl). 2013; 229(2): 275-83. [DOI:10.1007/s00213-013-3096-7] [PMID]

22. Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L, Engel JA. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict Biol. 2007; 12(1): 6-16. [DOI:10.1111/j.1369-1600.2006.00041.x] [PMID]

23. Blázquez E, Velázquez E, Hurtado-Carneiro V, Miguel Ruiz-Albusac J. Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol (Lausanne). 2014; 5: 161. [DOI:10.3389/fendo.2014.00161] [PMID] []

24. Ustione A, Piston DW, Harris PE. Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet. Mol Endocrinol. 2013; 27(8): 1198-207. [DOI:10.1210/me.2013-1083] [PMID] []

25. Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003; 52(10): 2546-53. [DOI:10.2337/diabetes.52.10.2546] [PMID]